IXICO contract wins provide near-total revenue visibility for current year

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and analytics group, has secured £1.3 million of new contract work that its broker says should take the company's order book close to full coverage of its current-year revenue forecast. The two wins, an Alzheimer's disease biomarker validation contract and an extension to an existing phase II Huntington's disease clinical trial, were announced earlier on Wednesday.